B Cell Suppression in Primary Glomerular Disease

Advances in Chronic Kidney Disease

Volumn 21, Issue 2, 2014, Pages 166-181

  Rood, Ilse M ^a   Hofstra, Julia M ^a   Deegens, Jeroen K J ^a   Wetzels, Jack F M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Focal segmental glomerulosclerosis; Membranous nephropathy; Minimal change disease; Rituximab

Indexed keywords

AZATHIOPRINE; BELIMUMAB; CD19 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; EPRATUZUMAB; LEVAMISOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCRELIZUMAB; PREDNISONE; RITUXIMAB; STEROID; TACROLIMUS;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; APOPTOSIS; B LYMPHOCYTE; CLINICAL PRACTICE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONGENITAL NEPHROTIC SYNDROME; CONTROLLED CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; DRUG EFFICACY; END STAGE RENAL DISEASE; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; MEMBRANOUS GLOMERULONEPHRITIS; MINIMAL CHANGE GLOMERULONEPHRITIS; MONOTHERAPY; NEPHROTIC SYNDROME; OBSERVATIONAL STUDY; OFF LABEL DRUG USE; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; RELAPSE; REMISSION; REVIEW; TREATMENT RESPONSE;

FOCAL SEGMENTAL GLOMERULOSCLEROSIS; MEMBRANOUS NEPHROPATHY; MINIMAL CHANGE DISEASE; RITUXIMAB;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; GLOMERULONEPHRITIS; GLOMERULONEPHRITIS, MEMBRANOUS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; NEPHROSIS, LIPOID; OLIGONUCLEOTIDES; PREDNISONE; RECOMBINANT FUSION PROTEINS;

EID: 84896828071     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2014.01.005     Document Type: Review

References (63)

1. Braden G.L., Mulhern J.G., O'Shea M.H., Nash S.V., Ucci A.A., Germain M.J. Changing incidence of glomerular diseases in adults. Am J Kidney Dis 2000, 35(5):878-883.
2. Glassock R.J. Human idiopathic membranous nephropathy-a mystery solved?. N Engl J Med 2009, 361(1):81-83.
3. Glassock R.J. Secondary membranous glomerulonephritis. Nephrol Dial Transplant 1992, 7(suppl 1):64-71.
4. Beck L.H., Bonegio R.G., Lambeau G., et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009, 361(1):11-21.
5. Hofstra J.M., Wetzels J.F. Anti-PLA(2)R antibodies in membranous nephropathy: ready for routine clinical practice?. Neth J Med 2012, 70(3):109-113.
6. Murtas C., Bruschi M., Candiano G., et al. Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy. Clin J Am Soc Nephrol 2012, 7(9):1394-1400.
7. Yoshizawa N., Kusumi Y., Matsumoto K., et al. Studies of a glomerular permeability factor in patients with minimal-change nephrotic syndrome. Nephron 1989, 51(3):370-376.
8. Wei C., El Hindi S., Li J., et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011, 17(8):952-960.
9. Benz K., Dotsch J., Rascher W., Stachel D. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 2004, 19(7):794-797.
10. Nozu K., Iijima K., Fujisawa M., Nakagawa A., Yoshikawa N., Matsuo M. Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol 2005, 20(11):1660-1663.
11. Vallerskog T., Gunnarsson I., Widhe M., et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol 2007, 122(1):62-74.
12. Vincenti F., Cohen S.D., Appel G. Novel B cell therapeutic targets in transplantation and immune-mediated glomerular diseases. Clin J Am Soc Nephrol 2010, 5(1):142-151.
13. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2012, 2:139-274.
14. Hofstra J.M., Wetzels J.F. Introduction of a cyclophosphamide-based treatment strategy and the risk of ESRD in patients with idiopathic membranous nephropathy: a nationwide survey in the Netherlands. Nephrol Dial Transplant 2008, 23(11):3534-3538.
15. Hofstra J.M., Wetzels J.F. Alkylating agents in membranous nephropathy: efficacy proven beyond doubt. Nephrol Dial Transplant 2010, 25(6):1760-1766.
16. Van den Brand J.A., Van Dijk P.R., Hofstra J.M., Wetzels J.F.M. Long term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy. J Am Soc Nephrol 2013, 25(1):150-158.
17. Hofstra J.M., Fervenza F.C., Wetzels J.F. Treatment of idiopathic membranous nephropathy. Nat Rev Nephrol 2013, 9(8):443-458.
18. Remuzzi G., Chiurchiu C., Abbate M., Brusegan V., Bontempelli M., Ruggenenti P. Rituximab for idiopathic membranous nephropathy. Lancet 2002, 360(9337):923-924.
19. Ruggenenti P., Chiurchiu C., Abbate M., et al. Rituximab for idiopathic membranous nephropathy: who can benefit?. Clin J Am Soc Nephrol 2006, 1(4):738-748.
20. Cravedi P., Ruggenenti P., Sghirlanzoni M.C., Remuzzi G. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2007, 2(5):932-937.
21. Fervenza F.C., Cosio F.G., Erickson S.B., et al. Rituximab treatment ofidiopathic membranous nephropathy. Kidney Int 2008, 73(1):117-125.
22. Fervenza F.C., Abraham R.S., Erickson S.B., et al. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol 2010, 5(12):2188-2198.
23. Ruggenenti P., Cravedi P., Chianca A., et al. Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol 2012, 23(8):1416-1425.
24. Segarra A., Praga M., Ramos N., et al. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin J Am Soc Nephrol 2009, 4(6):1083-1088.
25. Beck L.H., Fervenza F.C., Beck D.M., et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011, 22(8):1543-1550.
26. ClinicialTrials.gov: A service of the U.S. National Institutes of Health. Available at. Accessed: July 1, 2013. http://www.clinicaltrials.gov.
27. Stohl W., Hiepe F., Latinis K.M., et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012, 64(7):2328-2337.
28. Schwartz M.M. The role of podocyte injury in the pathogenesis of focal segmental glomerulosclerosis. Ren Fail 2000, 22(6):663-684.
29. D'Agati V.D., Fogo A.B., Bruijn J.A., Jennette J.C. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis 2004, 43(2):368-382.
30. Deegens J.K., Wetzels J.F. Immunosuppressive treatment of focal segmental glomerulosclerosis: lessons from a randomized controlled trial. Kidney Int 2011, 80(8):798-801.
31. Prytula A., Iijima K., Kamei K., et al. Rituximab in refractory nephrotic syndrome. Pediatr Nephrol 2010, 25(3):461-468.
32. Ito S., Kamei K., Ogura M., et al. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol 2011, 26(10):1823-1828.
33. Gulati A., Sinha A., Jordan S.C., et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol 2010, 5(12):2207-2212.
34. Kemper M.J., Gellermann J., Habbig S., et al. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant 2012, 27(5):1910-1915.
35. Ito S., Kamei K., Ogura M., et al. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome. Pediatr Nephrol 2013, 28(2):257-264.
36. Tellier S., Brochard K., Garnier A., et al. Long-term outcome of children treated with rituximab for idiopathic nephrotic syndrome. Pediatr Nephrol 2013, 28(6):911-918.
37. Kronbichler A., Konig P., Busch M., Wolf G., Mayer G., Rudnicki M. Rituximab in adult patients with multi-relapsing/steroid-dependent minimal change disease and focal segmental glomerulosclerosis: a report of 5 cases. Wien Klin Wochenschr 2013, 125(11-12):328-333.
38. Munyentwali H., Bouachi K., Audard V., et al. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int 2013, 83(3):511-516.
39. Sinha A., Bagga A., Gulati A., Hari P. Short-term efficacy of rituximab versus tacrolimus in steroid-dependent nephrotic syndrome. Pediatr Nephrol 2012, 27(2):235-241.
40. Kamei K., Ito S., Nozu K., et al. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol 2009, 24(7):1321-1328.
41. Fujinaga S., Hirano D., Nishizaki N., et al. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine. Pediatr Nephrol 2010, 25(3):539-544.
42. Kyrieleis H.A., Lowik M.M., Pronk I., et al. Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. Clin J Am Soc Nephrol 2009, 4(10):1593-1600.
43. Ravani P., Ponticelli A., Siciliano C., et al. Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int 2013, 84(5):1025-1033.
44. Sellier-Leclerc A.L., Baudouin V., Kwon T., et al. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood-follow-up after CD19 recovery. Nephrol Dial Transplant 2012, 27(3):1083-1089.
45. Takei T., Itabashi M., Moriyama T., et al. Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults. Nephrol Dial Transplant 2013, 28(5):1225-1232.
46. Ravani P., Magnasco A., Edefonti A., et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 2011, 6(6):1308-1315.
47. Kari J.A., El-Morshedy S.M., El-Desoky S., Alshaya H.O., Rahim K.A., Edrees B.M. Rituximab for refractory cases of childhood nephrotic syndrome. Pediatr Nephrol 2011, 26(5):733-737.
48. Tarshish P., Tobin J.N., Bernstein J., Edelmann C.M. Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis. A report of the International Study of Kidney Disease in Children. Pediatr Nephrol 1996, 10(5):590-593.
49. Magnasco A., Ravani P., Edefonti A., et al. Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol 2012, 23(6):1117-1124.
50. Fernandez-Fresnedo G., Segarra A., Gonzalez E., et al. Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2009, 4(8):1317-1323.
51. Bagga A., Sinha A., Moudgil A. Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med 2007, 356(26):2751-2752.
52. Maas R.J., Deegens J.K., van den Brand J.A., Cornelissen E.A., Wetzels J.F. A retrospective study of focal segmental glomerulosclerosis: clinical criteria can identify patients at high risk for recurrent disease after first renal transplantation. BMC Nephrol 2013, 14:47.
53. Ponticelli C. Recurrence of focal segmental glomerular sclerosis (FSGS) after renal transplantation. Nephrol Dial Transplant 2010, 25(1):25-31.
54. Araya C.E., Dharnidharka V.R. The factors that may predict response to rituximab therapy in recurrent focal segmental glomerulosclerosis: a systematic review. J Transplant 2011, 2011:374213.
55. Kumar J., Shatat I.F., Skversky A.L., et al. Rituximab in post-transplant pediatric recurrent focal segmental glomerulosclerosis. Pediatr Nephrol 2013, 28(2):333-338.
56. Guigonis V., Dallocchio A., Baudouin V., et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 2008, 23(8):1269-1279.
57. Brezinschek H.P., Rainer F., Brickmann K., Graninger W.B. B lymphocyte-typing for prediction of clinical response to rituximab. Arthritis Res Ther 2012, 14(4):R161.
58. Breedveld F., Agarwal S., Yin M., et al. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol 2007, 47(9):1119-1128.
59. Sugiura H., Takei T., Itabashi M., et al. Effect of single-dose rituximab on primary glomerular diseases. Nephron Clin Pract 2011, 117(2):c98-c105.
60. Dillon J.J., Hladunewich M., Haley W.E., Reich H.N., Cattran D.C., Fervenza F.C. Rituximab therapy for Type I membranoproliferative glomerulonephritis. Clin Nephrol 2012, 77(4):290-295.
61. Hoxha E., Stahl R.A., Harendza S. Rituximab in adult patients with immunosuppressive-dependent minimal change disease. Clin Nephrol 2011, 76(2):151-158.
62. Tsagalis G., Psimenou E., Nakopoulou L., Laggouranis A. Combination treatment with plasmapheresis and rituximab for recurrent focal segmental glomerulosclerosis after renal transplantation. Artif Organs 2011, 35(4):420-425.
63. Audard V., Kamar N., Sahali D., et al. Rituximab therapy prevents focal and segmental glomerulosclerosis recurrence aftera second renal transplantation. Transpl Int 2012, 25(5):e62-e66.